Full text

Turn on search term navigation

© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Background and Objectives: Peritoneal dialysis (PD) is a renal replacement therapy modality in which the dialysis dose can be individually adapted according to the patients’ residual kidney function (RKF). RKF is a crucial factor for technique and patient survival. Pharmacological strategies aimed at slowing the loss of RKF in patients on PD are limited. Therefore, we aimed to assess the potential effects and safety of sodium–glucose cotransporter 2 (SGLT-2) inhibitors on the preservation of RKF in patients with and without type 2 diabetes mellitus (T2DM) on PD during an average follow-up of 6 months. Materials and Methods: In this retrospective observational, single-center study on real-world data, we included patients from the Peritoneal Dialysis Unit of the Hospital General Universitario de Ciudad Real, who started treatment with SGLT-2 inhibitors during the period from December 2022 to December 2023. Data on analytical and clinical parameters, RKF, and peritoneal membrane transport function were retrospectively collected at months 0, 3, and 6. Results: Out of 31 patients in our unit, 16 prevalent patients initiated treatment with SGLT-2 inhibitors (13 empagliflozin and 3 dapagliflozin). A total of 62.5% were male and the mean age was 67.3 years. The baseline peritoneal ultrafiltration was higher in the non-diabetic patient (NDMP) group than in the diabetic patient (DMP) group. However, the residual diuresis volume, 24 h residual renal clearance rate of urea in urine, and 24 h proteinuria were higher in the DMP group than in the NDMP group. At the sixth month, patients in both groups preserved RKF and diuresis, with a trend towards a non-significant reduction in proteinuria and blood pressure. Only two patients of the DMP group presented adverse effects. Conclusions: The use of SGLT-2 inhibitors in our sample of patients with and without T2DM on PD appears to be safe and effective to preserve RKF.

Details

Title
Effects of Sodium–Glucose Cotransporter 2 Inhibitors in Diabetic and Non-Diabetic Patients with Advanced Chronic Kidney Disease in Peritoneal Dialysis on Residual Kidney Function: In Real-World Data
Author
Esperanza Moral Berrio 1   VIAFID ORCID Logo  ; José C De La Flor 2   VIAFID ORCID Logo  ; Minerva Arambarri Segura 1 ; Rodríguez-Doyágüez, Pablo 3 ; Alberto Martínez Calero 1 ; Zamora, Rocío 4 ; Cieza-Terrones, Michael 5   VIAFID ORCID Logo  ; Yuste-Lozano, Claudia 6 ; María Dolores Sánchez de la Nieta García 1 ; Javier Nieto Iglesias 1 ; Carmen Vozmediano Poyatos 1 

 Department of Nephrology, Hospital General Universitario de Ciudad Real, 13005 Ciudad Real, Spain; [email protected] (E.M.B.); [email protected] (M.A.S.); [email protected] (A.M.C.); [email protected] (M.D.S.d.l.N.G.); [email protected] (J.N.I.); [email protected] (C.V.P.) 
 Department of Nephrology, Hospital Central de la Defensa Gómez Ulla, 28047 Madrid, Spain; Department of Medicine and Medical Specialties, Faculty of Medicine, Alcala University, 28805 Madrid, Spain 
 Department of Nephrology, Guadalajara Center Dialysis, AVERICUM, 19003 Guadalajara, Spain; [email protected] 
 Department of Nephrology, Hospital Universitario General Villalba, 28400 Madrid, Spain; [email protected] 
 Faculty of Medicine, Peruana Cayetano Heredia University, Lima 15002, Peru; [email protected] 
 Department of Nephrology, Hospital 12 de Octubre, 28041 Madrid, Spain; [email protected] 
First page
1198
Publication year
2024
Publication date
2024
Publisher
MDPI AG
ISSN
1010660X
e-ISSN
16489144
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3098088926
Copyright
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.